Diagnosis of congenital aortic coarctation in advanced age is rare. In this occasion, indication to invasive treatment should be timely pondered and procedure risks may overcome its possible benefits. When maximal medical therapy does not suffice and symptoms are exacerbating, percutaneous treatment may represent the only alternative.
In the case herein reported, in spite of the advanced age, the patient did not appear to have developed any end-stage organ failure and her left ventricular function and structure were slightly altered. We were well aware of the possible unresponsiveness of such an inveterate systemic hypertension. In reality, a percutaneous attempt at handling the coarctation was deemed to be worthwhile and at a containable procedural risk. In fact, in spite of the tight coarctation and tortuosity of the aorta, lack of thick calcifications at the level of the lesion suggested a preserved elasticity of the aortic tissue.
Although we present just immediate and short term follow-up data, systemic blood pressure was normalized acutely and remained well controlled in the following weeks with a very much reduced pharmacological intake.
To our knowledge, this is the first report of percutaneous handling of a congenital aortic coarctation at such an adult age.
Our experience could suggest a more aggressive treatment of symptomatic aortic coarctation even in patients with more advanced age and whenever the anatomy of the lesion seems amenable to a percutaneous approach.
Long-term follow-up data will be necessary to consolidate the success of the procedure and confirm the persistence in arterial blood pressure reduction. 1 published an interesting review in this journal on the relevance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) for hypertensive disorders of pregnancy (HDP) and its complications. They have concluded that failure of regulation of the MMP/TIMP system in controlling the extracellular matrix remodeling may lead to diverse pathology, such as gestational hypertension (GH) and preeclampsia (PE). We would like to contribute additional, supportive data regarding plasma and genetic alterations in the MMP/TIMP system in HDP [2] [3] [4] ( Table 1) .
Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs genetic polymorphisms and plasma levels in hypertensive disorders of pregnancy
Higher MMP-9 levels in GH 2 are in agreement with our prior findings reporting elevated pro-MMP-9 in women with GH. 5 Moreover, higher TIMP-1 levels were observed in GH and PE. 2 However, no significant differences were observed in MMP-9/ TIMP-1 ratios. 2 Conversely, while we have not previously found significant differences in pro-MMP-2 and TIMP-2 levels in HDP, 5 we recently reported higher MMP-2 and TIMP-2 concentrations in women with PE, but there were no differences in MMP-2/TIMP-2 ratios. 3 In addition, we reported higher MMP-2 levels and MMP-2/ TIMP-2 ratios in GH. 3 Importantly, different methods may be used to assess MMP and TIMP levels, as highlighted by Karthikeyan et al. 1 Although we have previously evaluated MMP activity by zymography, 5 we have recently performed enzyme-linked immunosorbent assays (ELISAs) to measure plasma MMP-9 2 and MMP-2 3 levels. Moreover, ELISA from different brands may detect distinct TIMP epitopes. 2, 3, 5 Although differences among studies may rely on different detection methods, they could also be due to differences in the gestational age at sampling (Table 1) , as studies have observed changes in MMP-2 and MMP-9 levels throughout gestation. 6, 7 Interestingly, many reports have shown that the C-1562T (rs3918242) and À 90(CA) 13-25 (rs2234681) polymorphisms in the MMP-9 promoter, and the C-1306T (rs243865) and C-735T (rs2285053) polymorphisms in the MMP-2 promoter may affect gene and protein expressions of MMP-9 and MMP-2, respectively. As MMP activity can be regulated transcriptionally, we have investigated the role of these functional genetic polymorphisms of MMPs in HDP. [2] [3] [4] We reported that the CT genotype and T allele for the C-1562T polymorphism were more commonly found in GH, but not in PE, compared with healthy pregnant women, suggesting that this polymorphism is associated only with GH. 4 We also found evidence that genetic variants for the À 90(CA) 13-25 polymorphism may affect plasma MMP-9 concentrations and MMP-9/TIMP-1 ratios in GH.
2 MMP-2 genetic variations of the C-1306T and C-735T polymorphisms were also associated with altered plasma MMP-2 and TIMP-2 concentrations in PE. 3 We have also recently characterized interactions between MMP-9 and VEGF genotypes that were associated with PE, 8 but not with GH; however, these interactions did not affect plasma MMP-9 levels in HDP. 9 Given the importance of circulating MMPs and TIMPs in hypertension, 10 we expect that further epistasis analysis including MMP and TIMP polymorphisms may explain MMP/TIMP ratios.
In summary, the findings cited here may contribute to the review of Karthikeyan et al. 1 and with additional relevant information to HDP susceptibility.
